JP2018531984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531984A5 JP2018531984A5 JP2018522570A JP2018522570A JP2018531984A5 JP 2018531984 A5 JP2018531984 A5 JP 2018531984A5 JP 2018522570 A JP2018522570 A JP 2018522570A JP 2018522570 A JP2018522570 A JP 2018522570A JP 2018531984 A5 JP2018531984 A5 JP 2018531984A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- botulinum toxin
- component
- positively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021162802A JP2022008814A (ja) | 2015-10-29 | 2021-10-01 | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248255P | 2015-10-29 | 2015-10-29 | |
| US62/248,255 | 2015-10-29 | ||
| PCT/US2016/059492 WO2017075468A1 (en) | 2015-10-29 | 2016-10-28 | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162802A Division JP2022008814A (ja) | 2015-10-29 | 2021-10-01 | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531984A JP2018531984A (ja) | 2018-11-01 |
| JP2018531984A5 true JP2018531984A5 (enExample) | 2019-12-12 |
| JP6955491B2 JP6955491B2 (ja) | 2021-10-27 |
Family
ID=58630886
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522570A Active JP6955491B2 (ja) | 2015-10-29 | 2016-10-28 | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
| JP2021162802A Pending JP2022008814A (ja) | 2015-10-29 | 2021-10-01 | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162802A Pending JP2022008814A (ja) | 2015-10-29 | 2021-10-01 | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180311333A1 (enExample) |
| EP (1) | EP3368071B1 (enExample) |
| JP (2) | JP6955491B2 (enExample) |
| KR (1) | KR102794108B1 (enExample) |
| CN (1) | CN109069608A (enExample) |
| AU (2) | AU2016343748A1 (enExample) |
| BR (1) | BR112018008684A2 (enExample) |
| CA (1) | CA3003447A1 (enExample) |
| CO (1) | CO2018005361A2 (enExample) |
| DK (1) | DK3368071T3 (enExample) |
| ES (1) | ES2907652T3 (enExample) |
| IL (2) | IL259016A (enExample) |
| MX (1) | MX2018005256A (enExample) |
| RU (1) | RU2018119765A (enExample) |
| SG (2) | SG11201803566TA (enExample) |
| WO (1) | WO2017075468A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200707352B (en) * | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| SG177357A1 (en) * | 2009-06-25 | 2012-02-28 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
| HRP20181869T1 (hr) * | 2009-10-21 | 2019-01-11 | Revance Therapeutics, Inc. | Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina |
| DK3368071T3 (da) | 2015-10-29 | 2022-05-02 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning |
| JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス， インコーポレイテッド | 大型薬剤の経皮送達 |
| AU2018237198B2 (en) * | 2017-03-22 | 2022-09-01 | Bonti, Inc. | Botulinum neurotoxins for use in therapy |
| WO2018213710A1 (en) | 2017-05-18 | 2018-11-22 | Revance Therapeutics, Inc. | Methods of treatment for cervical dystonia |
| WO2018236873A1 (en) | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| US20200390871A1 (en) * | 2017-11-03 | 2020-12-17 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect |
| AU2018378465B2 (en) * | 2017-12-04 | 2025-05-29 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| AU2019337656A1 (en) * | 2018-09-13 | 2021-05-06 | Allergan, Inc. | Methods for treatment of masseter muscle hypertrophy |
| AU2020274082A1 (en) * | 2019-05-14 | 2022-01-20 | Eirion Therapeutics, Inc. | Delaying peak effect and/or extending duration of response |
| BR112022018670A2 (pt) * | 2020-03-18 | 2022-11-01 | Revance Therapeutics Inc | Métodos de toxina botulínica injetável para tratar cefaleia |
| KR102397708B1 (ko) * | 2020-04-29 | 2022-05-16 | 한국화학연구원 | 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물 |
| KR102324855B1 (ko) * | 2020-05-20 | 2021-11-11 | 오스템임플란트 주식회사 | 보툴리눔 독소를 포함하는 약제학적 액상 조성물 |
| AU2021360788A1 (en) * | 2020-10-13 | 2023-06-01 | Revance Therapeutics, Inc. | Methods for treating cervical dystonia |
| KR102266384B1 (ko) * | 2021-01-25 | 2021-06-21 | 주식회사 울트라브이 | 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제 |
| CA3209156A1 (en) * | 2021-02-21 | 2022-08-25 | Revance Therapeutics, Inc. | Methods of and compositions for treatment of upper limb spasticity |
| CN117561075A (zh) * | 2021-04-26 | 2024-02-13 | 上海科技大学 | 肉毒杆菌神经毒素的肌内注射组合物 |
| CA3238234A1 (en) * | 2021-11-15 | 2023-05-19 | Medytox Inc. | Botulinum neurotoxin composition |
| JP2025519507A (ja) * | 2022-06-10 | 2025-06-26 | メディトックス インク． | ボツリヌス毒素安定化組成物、それを含むボツリヌス毒素製剤及びそれに用いるためのポリペプチド |
| KR102714765B1 (ko) * | 2023-05-04 | 2024-10-11 | 주식회사 파마리서치바이오 | Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제 |
| WO2025064729A1 (en) * | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| EP1586329A1 (en) | 2000-02-08 | 2005-10-19 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| DE10043982A1 (de) * | 2000-09-05 | 2002-03-14 | Armin Maurer | Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| WO2010078242A1 (en) * | 2008-12-31 | 2010-07-08 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations |
| SG177357A1 (en) * | 2009-06-25 | 2012-02-28 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
| EP2661276B1 (en) * | 2011-01-07 | 2017-08-02 | Revance Therapeutics, Inc. | Topical composition comprising botulinum toxin and a dye |
| KR20140139010A (ko) * | 2012-03-22 | 2014-12-04 | 레반스 테라퓨틱스, 아이엔씨. | 국소 화학탈신경제를 이용한 주름 치료 방법 |
| US20140120077A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
| DK3368071T3 (da) | 2015-10-29 | 2022-05-02 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning |
-
2016
- 2016-10-28 DK DK16860952.7T patent/DK3368071T3/da active
- 2016-10-28 US US15/771,635 patent/US20180311333A1/en not_active Abandoned
- 2016-10-28 BR BR112018008684A patent/BR112018008684A2/pt active Search and Examination
- 2016-10-28 EP EP16860952.7A patent/EP3368071B1/en active Active
- 2016-10-28 MX MX2018005256A patent/MX2018005256A/es unknown
- 2016-10-28 JP JP2018522570A patent/JP6955491B2/ja active Active
- 2016-10-28 KR KR1020187014681A patent/KR102794108B1/ko active Active
- 2016-10-28 AU AU2016343748A patent/AU2016343748A1/en not_active Abandoned
- 2016-10-28 WO PCT/US2016/059492 patent/WO2017075468A1/en not_active Ceased
- 2016-10-28 ES ES16860952T patent/ES2907652T3/es active Active
- 2016-10-28 RU RU2018119765A patent/RU2018119765A/ru not_active Application Discontinuation
- 2016-10-28 SG SG11201803566TA patent/SG11201803566TA/en unknown
- 2016-10-28 CN CN201680072956.XA patent/CN109069608A/zh active Pending
- 2016-10-28 CA CA3003447A patent/CA3003447A1/en active Pending
- 2016-10-28 SG SG10202004337WA patent/SG10202004337WA/en unknown
-
2018
- 2018-04-29 IL IL259016A patent/IL259016A/en unknown
- 2018-05-23 CO CONC2018/0005361A patent/CO2018005361A2/es unknown
-
2021
- 2021-09-10 US US17/472,525 patent/US20220062400A1/en active Pending
- 2021-09-19 IL IL286472A patent/IL286472A/en unknown
- 2021-10-01 JP JP2021162802A patent/JP2022008814A/ja active Pending
-
2023
- 2023-10-06 AU AU2023241373A patent/AU2023241373A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531984A5 (enExample) | ||
| RU2018119765A (ru) | Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие | |
| JP2016540785A5 (enExample) | ||
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| HRP20241127T1 (hr) | Formulacije i doze pegilirane urikaze | |
| JP2015517488A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| WO2009046824A3 (en) | Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis | |
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| WO2009033668A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040068A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2018505882A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| WO2009033736A3 (en) | Use of met-enkephalin as a therapeutic agent | |
| JP2019509311A5 (enExample) | ||
| WO2009033712A3 (en) | Use of melanotan ii as a therapeutic agent | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| JP2013532729A5 (enExample) | ||
| WO2009033791A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2019529541A5 (enExample) | ||
| RU2016137292A (ru) | Схема применения соединения fgf-18 | |
| JP2015520196A5 (enExample) |